Physician profile
Ralph E Simms
NPI 1124146113
$1,181.76
in general payments reported to CMS, 2019-2025
17 companies · $66.60 in 2025
The $66.60 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.28 · 2020: $215 · 2021: $357 · 2022: $192 · 2023: $172 · 2024: $98.71 · 2025: $66.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $211.22 | 2021-2025 | Vraylar |
| Abbott Laboratories | $184.87 | 2021-2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $157.49 | 2019-2022 | |
| Pfizer INC. | $156.69 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $127.31 | 2019-2024 | Airsupra |
| Lundbeck LLC | $63.50 | 2022 | |
| Allergan, INC. | $55.26 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.59 | 2024-2025 | Caplyta |
| Eisai INC. | $37.04 | 2021 | |
| Axsome Therapeutics, INC. | $31.91 | 2025 | Auvelity |
| Athena Bioscience, LLC | $28.44 | 2024 | Nexiclon Xr |
| Novartis Pharmaceuticals Corporation | $18.48 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.86 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Lilly USA, LLC | $13.29 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12.72 | 2019 | |
| Horizon Therapeutics Plc | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Simms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.